Pa­tients ap­peal NI­H's re­jec­tion to use 'march-in' rights on Astel­las' prostate can­cer drug Xtan­di

NIH de­clined to use “march-in” rights to low­er the price of Astel­las’ and Pfiz­er’s prostate can­cer drug Xtan­di ear­li­er this week, and now the pa­tients be­hind the pe­ti­tion are ask­ing the fed­er­al agency to re­con­sid­er.

The ap­peal, dat­ed Thurs­day and shared with End­points News, was ad­dressed to HHS sec­re­tary Xavier Be­cer­ra and asked that HHS re­con­sid­er the pa­tients’ ap­peal di­rect­ly — and not as­sign NIH to re­ex­am­ine its own de­ci­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER